Are Ozempic and Wegovy the same drug?

Ozempic and Wegovy contain the same active ingredient — semaglutide — made by the same manufacturer. They are not different chemicals; they are two brand products built around one molecule, each with its own FDA-approved use, its own approved dose range, and its own place on an insurance formulary.

This page describes what is on the public record — the labels and FDA approvals. It contains no doses or titration schedules, and it is not a substitute for the clinician who knows your history.

Are Ozempic and Wegovy the same drug?

Yes, at the level of the molecule. Both are semaglutide, a GLP-1 receptor agonist. The difference is not the chemistry — it is the label: the brand name, the specific population the FDA approved each one for, and the dose range studied and approved for that use. “Same molecule” is an Established fact; it sits on the top rung of the Evidence Ladder because it is simply what the products are. What that sameness does not tell you is which product is appropriate for a given person — that is a separate, individual question.

What is each one approved for?

The approved uses are where the two brands separate. Ozempic is approved as a treatment for type 2 diabetes (improving blood-sugar control), and its label has since expanded to include reducing the risk of major cardiovascular events in adults with type 2 diabetes and heart disease, and — as of January 2025 — reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

Wegovy is approved for chronic weight management in adults (and adolescents) who meet weight criteria. Its label has also expanded: in March 2024 to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who have obesity or overweight, and in August 2025 (under accelerated approval) to treat a serious liver disease, MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis.

	Ozempic	Wegovy
Active molecule	Semaglutide	Semaglutide
Manufacturer	Novo Nordisk	Novo Nordisk
Primary approved use	Type 2 diabetes (blood-sugar control)	Chronic weight management
Added label uses	Cardiovascular risk reduction in T2D; kidney/CV protection in T2D + CKD	Cardiovascular risk reduction in obesity/overweight; MASH with fibrosis
Approved dose range	Lower maximum	Higher maintenance dose than Ozempic
Form (this comparison)	Once-weekly injection	Once-weekly injection

Doses are deliberately omitted here. The two products are not milligram-for-milligram interchangeable, and switching between them is a prescriber’s decision, not a self-substitution.

Why does the same molecule have two names?

Because a drug is approved for a use, not just as a chemical. When Novo Nordisk studied semaglutide for blood sugar in type 2 diabetes, that program became Ozempic (first FDA-approved in 2017). When higher-dose semaglutide was studied specifically for weight loss — the STEP trial program — that became Wegovy (FDA-approved in 2021). Separate trials, separate populations, separate approved dose ranges, so separate brands and labels, even though the syringe contains the same molecule.

This is the “Same Molecule, Different Product” principle: the molecule name describes the chemistry, but the brand and label describe what was actually tested, in whom, and at what dose — and that is what regulators approve and what clinicians prescribe against.

Why does insurance treat them differently?

Insurers reimburse against the approved indication, not the molecule. A plan that covers type 2 diabetes medicines may cover Ozempic for a person with diabetes, while the same plan may exclude or tightly restrict Wegovy because many plans historically carved out drugs taken purely for weight loss — even though it is the same semaglutide. Coverage rules, prior-authorisation criteria, and pricing differ by product and by plan, which is why two people can be prescribed “semaglutide” and face completely different out-of-pocket costs. (Note: semaglutide also exists in oral forms — Rybelsus for type 2 diabetes, and a newer oral Wegovy for weight management — each, again, with its own label.)

What does the evidence say each one does?

The efficacy claims for each approved use are Established — built on large randomised trials. For glycaemic control and cardiovascular risk in type 2 diabetes, the SUSTAIN program (including SUSTAIN-6) underpins the Ozempic side. For weight management, the STEP program (including STEP 1) underpins Wegovy, and the SELECT trial showed cardiovascular benefit in people with obesity but not diabetes. The molecule is the same; the evidence base is organised around each approved use.

Frequently asked questions

Is Wegovy just a higher dose of Ozempic? Roughly speaking, Wegovy is approved at a higher maintenance dose than Ozempic, and for a different purpose — but the products are not interchangeable, and you should never try to recreate one with the other. The approved dose ranges and titration were studied separately.

Can I switch from Ozempic to Wegovy (or back) myself? No. Even though it is the same molecule, the products differ in approved dose and indication. Any switch is a clinical decision your prescriber makes — doing it on your own risks dosing errors and gaps in monitoring.

If they’re the same molecule, is a cheaper “semaglutide” from elsewhere the same thing? No. “Same molecule” says nothing about purity, sterility, concentration accuracy, or who is accountable if something goes wrong. Compounded, “research-chemical,” or grey-market versions sit outside the approval and manufacturing oversight that apply to the branded products — a separate risk topic covered in the related chapter.

Are Ozempic and Wegovy the only semaglutide products? No. Semaglutide is also sold as Rybelsus — an oral tablet for type 2 diabetes, which in 2025 also gained an FDA indication to reduce cardiovascular risk — and an oral form of Wegovy for weight management has been approved more recently. Each carries its own label and approved use.

Questions to ask a clinician

• Given my health profile, which semaglutide product and indication actually fits — and why this one rather than the other?
• Is my prescription covered by my plan, and if not, what are the prior-authorisation or alternative options?
• If we ever switch products, how will dosing and monitoring change?
• What should I watch for in the first weeks, and how do I reach you if something feels wrong?

Red flags / when to seek care

The brand question is administrative; the safety questions are not. Regardless of which product you are prescribed:

• Be wary of any source offering “the same semaglutide” outside a pharmacy — identity, dose, and sterility are not guaranteed, and there is no accountability if you are harmed.
• Do not mix, split, or substitute products to save money or hit a target dose — the products are not interchangeable, and dosing errors are a real cause of severe side effects.
• Severe or persistent abdominal pain (especially radiating to the back, with repeated vomiting), signs of gallbladder trouble (upper-right abdominal pain, fever, yellowing skin or eyes), or inability to keep fluids down are reasons to contact a clinician promptly or seek urgent care — not to wait out.

If a price or a label looks too good to be true, treat that as the red flag, not the bargain.